Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma
Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD
Updated on 11/29/2025
The Voice of Stephen J. Williams, PhD
Since the formation of the LPBI group in 2012, we have set as a goal to digitally curate and ontologize the biomedical literature. These aspects of our mission, although not understandable to most at that time of our inception, was at the forefront of many academic efforts which became the springboard and initial conceptualization of today’s large language models. In select universities like University of Illinois, University of Delaware, and the Technion, academics and researchers at Microsoft and Google, were laying the framework for a semantic web, or Web 3.0. Another company at the forefront of this idea was a company springing forth from Mathematica, Wolfram Research. This idea for a semantic web would entail the processes of curation, digitization, and ontology creation. Their belief, such as ours, was a precursor and much needed key to the puzzle of moving language from machine learning algorithms to the generative transformers used by artificial intelligence.
However as most efforts in this genre focused on general language, our efforts at LPBI Group were focused on the biomedical field, as we understood, from 2012, that the biomedical literature was unique, and so a unique strategy had to be developed to semantically understand biomedical text, even though at the time of 2012 GPTs were not even a concept. However the potential for doing biomedical text analysis was there, and LPBI Group responded by developing a methodology of scientific curation which involved a multimodal strategy to curate, digitize, and ontologize biomedical findings and text.
It was about at the time of 2012 that other groups, mainly focused of drug development applications (for example at University of Indiana) recognized that new computational power of machine learning algorthims could be useful in analyzing complex biological questions. Please see our Synthetic Biology in Drug Discovery section of our Journal for more information on this. For instance, an early adopter of this strategy, a company called Data2Discovery, one of the earliest AI for drug discovery startups, stated
We are able to improve drug discovery now as well as demonstrating new fast-cycle AI-driven processes that will have a revolutionary impact on drug discovery if fully implemented. We have had some dramatic successes, but we are just starting to discover the impact that data, knowledge graphs, AI and machine learning can together have on drug discovery.
We need all the expertise of academics, consortia, AI companies and pharma to make his happen, and it’s going to require some serious investment, and a big change of thinking. But the opportunity to get drug discovery out of the death spiral and framed for data-driven success is too important to pass up.
However the LPBI Group was cognizant of these changes occuring and pivoted to the developing natural language processing arena as well as ideas for the developing Blockchain technology. This was more of a natural progression for the LPBI Group than a pivot (please read here).
This would be our Vision 2.0, to make biomedical text amenable for Natural Language Processing. We utilized a few strategies in this regard, partnering with a company who was developing NLP for biomedical text analysis, and developing in house machine learning and NLP methods using the Wolfram language environment. Our focus on structuring biomedical text (versus the highly structured genomics and omics data found in many omics related databanks) was prescient for the time. As NLP and machine learning efforts realized, biomedical text needs to have a structure much like genes, proteins and other molecular databases had been organized. Therefore it was realized that structured data was imperative for efficient NLP analysis, a crux for the new GPT which was being developed (and in this mind still is a crux for current GPT and LLM models when it comes to biomedical text analysis).
Our strategy using our scientific curation methodology (as described below in links form our founder Dr. Aviva Lev-Ari, was proven to be highly efficient and amenable to NLP analysis, as a pilot with an NLP company noticed. Most of the data they were using was unstructured and their first step involved annotation and structuring the text, as we had already performed for years. This was critical as our text was able to pull out more concepts, relationships, in a faster time than NLP on sources such as PubMed available text. We had also developed our own in house algorithms for NLP on our material, which is shown in some of our book offerrings and individual articles.
However with the advent of GPT it was thought all this was unnecessary. However this idea that our strategy was outdated or irrelevent in the era of GPT was wholly incorrect to the advocates of a sole GPT strategy to analyze biomedical text and data. It is now understood that structure is needed as some of biomedical-centric GPT projects would find out, such as BioGPT. We have many articles which attest to the lack of accuracy and efficiency of these GPT architectures (seen here). These include failure rates in many areas of healthcare and biomedicine by sole reliance on GPT,
It was realized by many in the biomedical arena, especially those involved in NLP efforts, that there was much value in the semantic web 3.0 idea, and this was readily picked up by those spearheading effort to incorporate knowledge graphs with the new generative AI or GPT technology. We have shown a clear example our scientific methodology of curation with ontology has better inference when combined with knowledge graphs and GPT than reliance on GPT alone
please read this article
Multiple Lung Cancer Genomic Projects Suggest New Targets, Research Directions for Non-Small Cell Lung Cancer
at https://pharmaceuticalintelligence.com/2014/09/05/multiple-lung-cancer-genomic-projects-suggest-new-targets-research-directions-for-non-small-cell-lung-cancer/
As shown here in this article
This update was performed by the following methods:
A. GPT 5 Text analysis and Reasoning
B. Insertion of Knowledge Graph on topic Curation of Genomic Analysis from Non Small Cell Lung Cancer Studies from
Nodus Labs using InfraNodus software
C. Domain Knowledge Expert evaluation of the Update outcomes
This article has the following Structure:
Part A: Introduction to LLM, Knowledge Graph software InfraNodus, ChatGPT5 and Background Information on curated material for Test Case
Part B: InfraNodus Analysis of manual curation and Knowledge Graph Creation
Part C: Chat GPT 5 Analysis of Manually Curated Material
Part D: Curation entitled Multiple Lung Cancer Genomic Projects Suggest New Targets, Research Directions for Non-Small Cell Lung Cancer originally published on 09/05/2014
Results of Article Update with GPT 5
1. GPT5 alone was not able to understand the goal of the article, namely to determine knowledge gaps in a particular research area involving 5 genomic studies on lung cancer patients
2. GPT5 alone was not able to group concepts or comonalities between biological pathways unless supplied with a manually curated list of KEGG pathways from a list of mutated genes. However this precluded any effect that fusion proteins had on the analysis and so GPT5 would only concentrate on mutated genes commonly found in literature
3. GPT was not able to access some of the open Access databases like NCBI Gene Ontology database
Results of Article Update with KnowledgeGraph presentation to GPT 5
4. As the Knowledge Graph understood the importance of fusion proteins and transversions, the knowledgegraph augmented the GPT analysis and so enriched the known pathways as well as could correctly identify the less represented pathways in the knowledge graph
5. This led to the identification of many novel signaling pathways not identified in the original analysis, and was able to perform this task with ease and speed
6. GPT with InfraNodus Analysis was able to propose pertinent questions for future research (the goal of the original curation) such as:
- How does the interaction between [[EGFR]] mutations and sex-specific gene alterations, including [[RBM10]], influence treatment outcomes in lung adenocarcinoma?
- How does the intersection of mutational patterns from smoking influence pathway activation in NSCLC, and can identifying these interactions improve targeted therapy development?
Novelty in comparison to Original article published on 09/05/2014
7. it appears that manual curation is necessary to assist in the building of relevant knowledge graphs in the biomedical fields to augment generative AI analysis
8. by itself, generative AI is not optimized for inference of higher concepts from biomedical text, and therefore, at this point, requires the input from human curators developing domain-specific knowledge graphs
9. The combination of ChatGPT5 and Knowledge graphs of this manually curated biomedical text added a further layer of complexity of gaps of knowledge not seen in the original curations including the need to study noncanonical signaling pathways like WNT and Hedgehog in smoker versus nonsmoker cohorts of lung cancer patients
The Voice of Aviva Lev-Ari, PhD, RN
LPBI Group’s Portfolio of Digital IP Assets as Proprietary Training Data Corpus for AI in Medicine, in Life Sciences, in Pharmaceutical and in Health Care Applications
The Portfolio of Digital IP Assets by Class is a rare, defensible asset, privately-held debt-free by LPBI Group’s founder. The content, aka a Data Corpus is best designed for the Training and Pre-Training of Foundation Multimodal Models in Health Care.
#HealthcareAI
#FoundationModels
#ProprietaryTrainingData
LPBI Group is offering transfer of ownership, in full, a privately held, multimodal healthcare training corpus leveraging propriety unique data set curated by domain experts and mapped to a living ontology for GenAI creating defensibility.
The Portfolio of IP spans:
- 6,250+ articles (~2.5MM views),
- 48 e‑books (EN/ES) (+152,000 page downloads),
- 100+ e‑Proceedings with +50 Tweet collections,
- 7,500+ biological images with expert context, and
- 300+ Audio podcasts on Life Sciences breakthroughs.
Each asset (Use Case: Scientific Article) has timestamps, author/role labels, crosslinks, and view histories.
- Metadata export exists; full text and media transfer via WordPress/Amazon account control for immediate ingestion.
- Rights are centrally assigned with explicit model‑training data by domain-aware for model implementation for Small Language Models or Large Language Models.
Strategic acquirers in Big Pharma of Vertical AI startups (i.e., LPBI Group) with data‑moat strategies
Pharma strategics Acquire LPBI’s end‑to‑end, rights‑clean healthcare knowledge base to accelerate R&D, medical affairs, and safety. Ideal for and with acceleration of R&D, medical affairs, and safety. Emphasize compliant internal copilots and evidence synthesis enabled by expert curation and living ontology. Close with rapid onboarding under NDA Metadata export plus full text/media transfer for rapid onboarding. Full acquisition only.
Subject: Buy the moat: full acquisition of expert healthcare corpus with clean rights
We’re selling the entire asset: a privately held, multimodal healthcare corpus with centralized training rights and an exportable ontology, validated on gene–disease–drug extraction. It’s ingest‑ready and transfers cleanly via account control plus a metadata export. If owning differentiated data is critical for your agent or workflow, we can provide a diligence preview under NDA.
compliant internal copilots and evidence synthesis enabled by expert curation and living ontology. Close with rapid onboarding under NDA
Five Examples of Domain-aware for model implementation for Small Language Models – English Edition & Spanish Edition
Series A: Cardiovascular Diseases ($515) – Six Volumes
https://www.amazon.com/gp/product/B07P981RCS?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks
Six Examples of Domain-aware in the Specialty of Cardiovascular Diseases
Perspectives on Nitric Oxide in Disease Mechanisms, 2013
http://www.amazon.com/dp/B00DINFFYC $75
Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation, 2015
http://www.amazon.com/dp/B018Q5MCN8 $75
Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics, 2015
http://www.amazon.com/dp/B018PNHJ84 $75
Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine, 2015
http://www.amazon.com/dp/B019UM909A $75
Pharmacological Agents in Treatment of Cardiovascular Diseases, 2018
https://www.amazon.com/dp/B07MGSFDWR $115
Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment, 2018
https://www.amazon.com/dp/B07MKHDBHF $100
Series B: Frontiers in Genomics ($200) – Two Volumes
https://www.amazon.com/gp/product/B0BSDPG2RX?ref_=dbs_p_pwh_rwt_anx_b_lnk&storeType=ebooks
Series C: Cancer & Oncology ($175) – Two Volumes
https://www.amazon.com/gp/product/B0BSDWVB3H?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks
Series D: Immunology ($325) – Four Volumes
https://www.amazon.com/gp/product/B08VVWTNR4?ref_=dbs_p_pwh_rwt_anx_b_lnk&storeType=ebooks
Series E: Patient-Centered Medicine ($274) – Four Volumes
https://www.amazon.com/gp/product/B0BSDW2K6C?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks
One Example of Domain-aware for model implementation for Large Language Models
Eighteen volumes in the English Edition and 19 volumes in the Spanish Edition including 2,728 articles by biomedical professionals are available.
The electronic books are collections of curated articles in biomedical science. The electronic Tables of Contents (eTOCs) of each volume was designed by a senior editor with expertise in the subjects covered in that volume. The curations use as sources published research findings in peer-reviewed scientific journals together with expert added interpretations.
The e-books are designed to make the latest research in the Five Bilingual BioMed e-Series – 37 volumes accessible to practicing health care professionals. These five e-Series cover the following medical specialties:
- Cardiovascular diseases and therapies,
- Genomics,
- Cancer etiology and oncological therapies,
- Immunology, and
- Patient-centered precision medicine.
The material in these volumes can greatly enhance medical education and provide a resource for continued updating and education for health care professionals. In addition to the 37 e-books, LPBI has published more than 6,000 articles in its online scientific journal “PharmaceuticalIntelligence.com”, which has received 2.5 million views since its launch in 4/2012, Top articles had more than 18,000 views.
The Portfolio is:
- rights‑clean,
- expert‑curated healthcare corpus
- mapped to a living Ontology,
- already packaged for immediate model ingestion and
- suitable for safe pre-training, evals, and fine‑tuning.
If healthcare domain data is on your roadmap, this is a rare, defensible asset worth a preview.
LPBI Group is offering transfer of ownership, in full, a privately held, multimodal healthcare training corpus leveraging propriety unique data set curated by domain experts and mapped to a living ontology for GenAI creating defensibility. It spans 6,250+ articles (~2.5MM views), 48 e‑books (EN/ES) (+151,000 page downloads), 100+ e‑proceedings with +50 tweet collections, 7,500+ biological images with expert context, and 300+ Audio podcasts on Life Sciences breakthroughs. Each asset has timestamps, author/role labels, crosslinks, and view histories. Rights are centrally assigned with explicit model‑training data by domain-aware for model implementation for Small LMs or LLMs. Metadata export exists; full text and media transfer via WordPress/Amazon account control for immediate ingestion.
Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA
Full acquisition only: LPBI Group’s Healthcare Training Data Corpus
- Scientific articles
- e‑Books in Medicine
- e‑Proceedings,
- Biological images
- Podcasts
#HealthcareAI #FoundationModels #TrainingData
Contact Founder: avivalev-ari@alum.berkeley.edu
PharmaceuticalIntelligence.com
About the Founder
- LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director, INTERACTIVE CHAT with Grok, created by xAI
https://pharmaceuticalintelligence.com/2025/04/30/interactive-chat-with-grok-created-by-xai-lpbi-groups-legacy-and-biography-of-aviva-lev-ari-phd-rn-founder-director/
For Recognitions and a DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see
- “Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)
https://pharmaceuticalintelligence.com/2025/04/29/show-thinking-by-ai-deep-research-the-ai-biography-description-of-aviva-lev-ari-phd-rn-founder-of-pharmaceuticalintelligence-com-by-perplexity-ai-and-by-googles-gemini-2/
Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma
On 11/14, 2025, Dr. Lev-Ari asked @Grok about AI Initiatives at a Big Pharma, i.e., Pfizer.
@Grok response is presented, below
URL SOURCE:
https://x.com/i/grok/share/0ol5VOJsEYs11baXq4xkzNb0h
Pfizer’s AI Initiatives Overview
Pfizer, a global pharmaceutical leader, has integrated artificial intelligence (AI) and machine learning (ML) across its operations to accelerate drug discovery, enhance clinical trials, improve manufacturing, and drive patient-centric innovations. These efforts aim to reduce development timelines, boost efficiency, and address challenges like rare disease detection. As of late 2025, Pfizer’s AI strategy emphasizes internal expertise, cloud-based tools (primarily with AWS), and cross-industry collaborations, with a focus on multimodal data analysis and generative AI. Below is a breakdown of key initiatives, drawn from recent developments.
1. Pfizer AI Cloud Transformation (PACT) Program Launched in 2021 with AWS, PACT is a prototyping accelerator for AI/ML applications in lab, clinical manufacturing, and supply chain efforts. It has pursued 14 projects, with five now in production. Key outcomes include:
- Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis.
- 55% reduction in infrastructure costs through cloud optimization.
- Exploration of virtual/augmented reality for training, with rapid prototyping to test feasibility. This program fosters “fail-fast” innovation, enabling quick iteration on ideas like AI-driven predictive modeling.
2. Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D, cutting years off traditional timelines (e.g., from 8–10 years to months for certain candidates).
- COVID-19 Initiatives: AI optimized molecular searches for PAXLOVID (oral antiviral), enabling intravenous-to-oral pivots. During vaccine development, the Safety Data Quality (SDQ) tool—a custom AI for clinical trial data management—saved a full month of analysis via the Breakthrough Change Accelerator sandbox.
- Precision Medicine and Subpopulation Identification: Advanced ML (classical and deep learning) analyzes molecular datasets from trials to predict patient responses, informing trial design, first-in-human studies, and oncology/inflammatory disease targeting. This has doubled clinical success rates to ~20% (vs. industry 7–10%).
- ML Research Hub: Pfizer’s Cambridge, MA-based Biomedical Data Science group builds internal talent for AI in genome sciences, predicting disease outcomes and treatment efficacy using techniques from tech giants like Google.
3. Clinical Trials and Regulatory Efficiency AI automates content creation across the drug lifecycle, from lab data to regulatory docs and patient booklets, ensuring quality and speed.
- Predictive Regulatory Tools: ML models forecast regulator queries, proactively addressing safety concerns to build trust and shorten approvals.
- Decentralized Trials: The “Clinical Trial Anywhere” model uses AI to integrate remote data (e.g., home health visits), improving recruitment/retention and generating real-world evidence.
- Inventory and Supply Chain: AI predicts vaccine storage issues, pioneered during COVID distribution.
4. Disease Detection and Diagnostics
- ATTR-CM Initiative: Through the ASPIRE collaboration (with Amyloidosis Research Consortium), AI analyzes EHRs, ECGs, and echocardiograms to detect transthyretin amyloid cardiomyopathy earlier, targeting underdiagnosed heart failure cases.
- Rare Diseases: ML models identify symptoms in large datasets, mapping the immune system for better predictions.
5. Generative AI and Operational Tools
- Charlie Platform: Rolled out in 2024 for marketing, this gen AI tool (named after co-founder Charles Pfizer) generates compliant content like emails, presentations, and medical article drafts. Trained on approved product data, it streamlines physician targeting and customer insights.
- Scientific Data Cloud: AWS-powered centralization of data/ML capabilities, enabling faster research and treating 1.3 billion patients in 2022. It supports gen AI via Amazon SageMaker/Bedrock for manufacturing efficiency.
- Global Health Grants: Through the Pfizer Foundation’s AI Learning Lab, funding supports AI for equitable healthcare access, e.g., biometric tools for community care.
6. Partnerships and Education
- Collaborations: With AWS for cloud AI; IMI Big Picture for a 3M-sample disease database; IIT Madras for the 2025 AIPM Symposium on AI in pharma (focusing on drug discovery and precision medicine).
- Talent and Events: Hosting webinars on AI in manufacturing (e.g., predictive maintenance, regulatory submissions) and engaging leaders like Dr. Subha Madhavan on AI for biomedical data integration.
- Strategic Focus: $500M R&D reinvestment by 2026 targets AI for productivity, part of $7.7B cost savings. Emphasis on ethical AI, diverse datasets, and competing with global biotech advances (e.g., China’s AI in CRISPR).
Pfizer’s approach balances operational efficiency with transformative R&D, positioning AI as a core enabler rather than a standalone focus. Ongoing investments, like cloud migrations saving $47M annually and reducing CO2 emissions, underscore sustainability. For the latest, monitor Pfizer’s investor updates or events like AWS re:Invent.
Responsiveness to Big Pharma AI Initiatives by LPBI Group’s Digital IP Portfolio:
- Scientific articles
- e‑Books in Medicine
- e‑Proceedings,
- Biological images
- Podcasts
| AI Initiative at Big Pharma
i.e., Pfizer
Composed @Grok |
LPBI Group’s Digital IP Asset:
Journal articles
N = 6,250
Composed by Aviva Lev-Ari |
| Generative AI tools
that save scientists up to 16,000 hours annually in literature searches and data analysis. |
Generative AI tools searching LPBI’s Proprietary data in addition to Public Domain data sources
Journal ONTOLOGY used to optimize context classification selected for search |
| Drug Discovery and Development Acceleration
Pfizer uses AI, supercomputing, and ML to streamline R&D timelines |
– Run prompts by category of research on the following three dyads
– Run ML across categories of research for these three dyads
-Gene-disease
-Disease-drug
-Gene-drug
|
| Clinical Trials and Regulatory Efficiency AI:
-Predictive Regulatory Tools
-Decentralize Trials
-inventory management |
Curation competences:
- content creation across the drug lifecycle, from lab data to regulatory docs
|
| Disease Detection and Diagnostics:
– ATTR-CM Initiative
– Rare diseases |
Heart Failure Diagnosis by Early detection of transthyretin amyloid cardiomyopathy
– Journal published ~30 curations by Dr. Larry on this subject ATTR-CM
– Run NLP on this Corpus
Rare diseases:
Journal published 560 articles on Rare diseases
– Run ML on this Corpus |
| Generative AI and Operational Tools:
– Charlie Platform
– Scientific Data Cloud AWS powered ML on centralized data
– Amazon’s SageMaker /Bedrock for Manufacturing efficiency
– Global Health Grants:
Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care |
Content generated in the Journal can become “generated compliant content” if run on the Charlie Platform.
– For REUSE content in context
Entire Corpus of 9 Giga bytes can be ingested to Pfizer Foundation’s AI Learning Lab
– Run prompts against it
– Journal’s Content to be used for Internal staff expertise development
– Journal’s Content for Leadership development |
| Partnerships and Education
– Collaborations: IMI Big Picture for 3M – sample disease database
– AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine
– Webinars of AI for biomedical data integration
– Webinar on AI in Manufacturing |
The Journal had published 547 articles in Precision Medicine
The Journal had published 1,114 articles in Drug Discovery
The Journal had published 701 articles in Drug Delivery
The Journal had published 3,615 articles on subject matter “Disease”
The Journal had published 738 articles on Biomedical topics
The Journal had published 425 articles on Artificial Intelligence (AI) |
| Strategic Focus:
– $500M R&D reinvestment by 2026 targets AI for Productivity
– Part of $7.7B cost savings
– Ethical AI, diverse DBs
– Global biotech advances: China’s AI in CRISPR |
The Journal had published 432 articles on CRISPR
Productivity derived from Journal’s content:
– As a result of the fact that ~70% of the Journal’s articles are curations written by Domain Knowledge Experts subjectively expressing theirs clinical interpretations of basic and primary research – the productivity of the knowledge workers at any Big Pharma would increase vastly.
– If Grok and Claude would run on LPBI Group’s Digital IP Corpus, a scientific revolution will emerge
– It is not combinatorics applied to molecules with 98% futile results!!!
it is the IQ of Gifted HUMANS, of domain knowledge experts generating content using individual CREATIVITY no Quantum or Super Intelligence which is not in existence, YET.
– Foundation Models in Healthcare depends on the OUTPUT of the human creative mind. AI takes keyword (classic search) and concepts (semantic search) and run frequency of occurrence and predict the nest word, one word after the next one. |
@@@@@@@
| AI Initiative at Big Pharma
i.e., Pfizer |
LPBI Group’s Digital IP Asset:
e-Books
Domain-aware Editorials and Curations
|
| Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis. |
The electronic Table of Contents of every e-book is a CONCEPTUAL MASTER PIECE of one unique occurrence in Nature generated by the Editor, or the Editors that had
– Commissioned articles for the e-Book
– Had selected articles from collections of Categories of Research created by domain knowledge experts
– Had reviewed the TOTALITY of the Journal’s Ontology and found new concept to cover in the e-Book not originally planned
Had incorporated Highlights of Lectures given at 100 Conferences LPBI Group’s Dr. Lev-Ari and Dr. Willians had cover in Real Real, by invitation, only as PRESS.
– The vision of the Editor-in-Chief of the BioMed e-Series reflects the BIG PICTURE of Patient care delivery.
– UC, Berkeley PhD’83
– Knowledge student and Knowledge worker, 10/1970 to Present
– Conceptual pioneer of 26 algorithms in Decision Science of Operations Management decision support systems
– 2005 to Present in the Healthcare field.
– 2005-2012: Clinical Nurse Manager in Post-acute SNF settings and Long-term Acute care Hospital Supervisor – had developed a unique view on Diagnosis, Therapeutics and Patient care delivery
– The BioMed e-Series is the EPITOM of human CREATIVITY in Healthcare an OPUS MAGNUM created by collaboration of top Scientists, Physicians and MD/PhDs
– The 48 e-Books Published by LPBI Group – represent the ONLY one Publisher on Amazon.com with +151,000 pages downloaded since the 1st e-book published on 6/2013 and since Pay-per-View was launched by Amazon.com in 2016. |
| Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines |
Two volumes on the BioMed e-Series were subjected to Medical Text Analysis with AI, ML, Natural Language Processing (NLP).
– Cancer, Volume 1 (In English, part of the Spanish Edition, Series C)
– Genomics, Volume 2 (In English, part of the Spanish Edition, Series B)
– GPT capabilities are warranted to attempt to subject to ML Analytics every book of the MUTUALLY EXCLUSIVE 48 URLs provided by Amazon.com to LPBI Group, the Publisher.
– 5 URLs for 5 Bundles in The English Edition: Series A,B,C,D,E – English Edition
– All books in each series – 5 Corpuses for domain-aware Small Language Model in English
– All books in each series – 5 Corpuses for domain-aware Small Language Model in Spanish
– 5 URLs for 5 Bundles in The Spanish Edition: Series A,B,C,D,E –Spanish Edition
|
| Clinical Trials and Regulatory Efficiency AI:
-Predictive Regulatory Tools
-Decentralize Trials
-inventory management |
|
| Disease Detection and Diagnostics:
– ATTR-CM Initiative
– Rare diseases |
– No one had attempted ML on every book, only two books were analyzed by ML.
– No one had attempted ML on all the Volumes in any of the 5 Series.
– No one had attempted ML on all the 48 books
– WHEN that will be done – a REVOLUTION on Disease Detection and Diagnostics will be seen for the first time because the totality of these 48 books represent the Brains of Human Experts
|
| Generative AI and Operational Tools:
– Charlie Platform
– Scientific Data Cloud AWS powered ML on centralized data
– Amazon’s SageMaker/Bedrock for Manufacturing efficiency
– Global Health Grants:
Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care |
Add the content of all the Books to Charlie Platform |
| Partnerships and Education
Collaborations: IMI Big Picture for 3M – sample disease database
AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine
Webinars of AI for biomedical data integration
Webinard on Ai in Manufacturing |
e-Books are the SOURCE for Education
– Offer the books as Partnership sustenance |
| Strategic Focus:
– $500M R&D reinvestment by 2026 targets AI for Productivity
– Part of $7.7B cost savings
– Ethical AI, diverse DBs
– Global biotech advances: China’s AI in CRISPR |
URLs for the English-language Edition by e-Series:
Series A: Cardiovascular Diseases ($515)
https://www.amazon.com/gp/product/B07P981RCS?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks
Series B: Frontiers in Genomics ($200)
https://www.amazon.com/gp/product/B0BSDPG2RX?ref_=dbs_p_pwh_rwt_anx_b_lnk&storeType=ebooks
Series C: Cancer & Oncology ($175)
https://www.amazon.com/gp/product/B0BSDWVB3H?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks
Series D: Immunology ($325)
https://www.amazon.com/gp/product/B08VVWTNR4?ref_=dbs_p_pwh_rwt_anx_b_lnk&storeType=ebooks
Series E: Patient-Centered Medicine ($274)
https://www.amazon.com/gp/product/B0BSDW2K6C?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks
|
@@@@@@@
| AI Initiative at Big Pharma
i.e., Pfizer |
LPBI Group’s Digital IP Asset:
e-Proceedings: N = +100, and
Tweet Collections: N = +50
|
| Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis. |
|
| Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines |
List of all e-Proceeding of +100 TOP Conferences in Biotech, in Medicine, in Genomics, in Precision Medicine
https://pharmaceuticalintelligence.com/press-coverage/part-two-list-of-biotech-conferences-2013-to-present/
In these conferences the Frontier of Science was presented, ofter BEFORE publication findings were revealed. These Proceedings are the ONLY written record of the events. They are privately-held, now for the first time available for Transfer of Ownership
The Tweet Collection are QUOTES of speakers on record. NOT ELSEWHERE available by name of speaker and affiliation |
| Clinical Trials and Regulatory Efficiency AI:
-Predictive Regulatory Tools
-Decentralize Trials
-inventory management |
|
| Disease Detection and Diagnostics:
– ATTR-CM Initiative
– Rare diseases |
|
| Generative AI and Operational Tools:
– Charlie Platform
– Scientific Data Cloud AWS powered ML on centralized data
– Amazon’s SageMaker/Bedrock for Manufacturing efficiency
– Global Health Grants:
Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care |
Ingest to Charlie Platform ALL e-Proceedings of ALL Conferences
Apply GPT:
Training Data:
– One conference at a time
– All Conference on ONE subject matter, i.e., Immunotherapy, Oncolytic Virus Immunotherapy, Immune Oncology |
| Partnerships and Education
– Collaborations: IMI Big Picture for 3M – sample disease database
– AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine
– Webinars of AI for biomedical data integration
– Webinar on Ai in Manufacturing |
Use Past Conference Agendas to build Future Conference Agendas
Use Speakers Lists to invite speakers/consultants to your events
Use topics covered in Conferences for Employee training & and in-house Leadership development |
| Strategic Focus:
– $500M R&D reinvestment by 2026 targets AI for Productivity
– Part of $7.7B cost savings
– Ethical AI, diverse DBs
– Global biotech advances: China’s AI in CRISPR |
Having access to +100 e-Proceedings vs Not having access to this resource is a make or break in fine-tuning Corporate Branding: All your competitors attended and had sent Speakers
- LPBI Group’s e-Proceedings is the only record in one URL
|
@@@@@@
| AI Initiative at Big Pharmas
i.e., Pfizer |
LPBI Group’s Digital IP Asset:
Biological Images selected by Experts embedded in original Text (Prior Art) |
| Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis. |
|
| Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines |
Gallery of ~8,000 Biological images and captions is a Treasure TROVE for scientific article writing, Presentation preparations. This Media Gallery is an Art collection of top Scholars in Medicine and Biology |
| Clinical Trials and Regulatory Efficiency AI:
-Predictive Regulatory Tools
-Decentralize Trials
-inventory management |
|
| Disease Detection and Diagnostics:
– ATTR-CM Initiative
– Rare diseases |
Gallery of ~8,000 Biological images and captions is a Treasure TROVE for Disease Detection and Diagnostics
|
| Generative AI and Operational Tools:
– Charlie Platform
– Scientific Data Cloud AWS powered ML on centralized data
– Amazon’s SageMaker/Bedrock for Manufacturing efficiency
– Global Health Grants:
Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care |
- Ingest into Charlie Platform the Media Gallery for generation of Medical article drafts
|
| Partnerships and Education
– Collaborations: IMI Big Picture for 3M – sample disease database
– AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine
– Webinars of AI for biomedical data integration
– Webinar on Ai in Manufacturing |
|
| Strategic Focus:
– $500M R&D reinvestment by 2026 targets AI for Productivity
– Part of $7.7B cost savings
– Ethical AI, diverse DBs
– Global biotech advances: China’s AI in CRISPR |
|
@@@@@@
| AI Initiative at Big Pharma
i.e., Pfizer |
LPBI Group’s Digital IP Asset:
Library of Audio and Video Podcasts
N = +300
|
| Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis. |
|
| Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines |
Review ALL SCIENTIFIC BREAKTHROUGHS
- Two criteria for Classifications used by Prof. Marcus W. Feldman and by Dr. Stephen J. Williams to generate the two classifications
https://pharmaceuticalintelligence.com/biomed-audio-podcast-library-lpbi-group/ |
| Clinical Trials and Regulatory Efficiency AI:
-Predictive Regulatory Tools
-Decentralize Trials
-inventory management |
|
| Disease Detection and Diagnostics:
– ATTR-CM Initiative
– Rare diseases |
| Aviva Lev-Ari, PhD, RN, Stephen J. Williams, PhD and Prof. Marcus W. Feldman |
Health Care Policy Analysis derived from the Farewell remarks from AMA President Jack Resneck Jr., MD | AMA 2023 Annual Meeting |
|
LISTEN to Audio Podcast
Future of Medicine
https://pharmaceuticalintelligence.com/2023/06/10/health-care-policy-analysis-derived-from-the-farewell-remarks-from-ama-president-jack-resneck-jr-md-ama-2023-annual-meeting/ |
| Generative AI and Operational Tools:
– Charlie Platform
– Scientific Data Cloud AWS powered ML on centralized data
– Amazon’s SageMaker/Bedrock for Manufacturing efficiency
– Global Health Grants:
Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care |
- Ingest to Charlie Platform all +300 Podcasts for Foundation’s AI Learning Lab
|
| Partnerships and Education
– Collaborations: IMI Big Picture for 3M – sample disease database
– AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine
– Webinars of AI for biomedical data integration
– Webinard on Ai in Manufacturing |
- Use Podcast for Education
- Use Podcast as Hybrid: Start presentation with a Podcast continue with a life interview
Examples of an Audio Podcast of Scientists on LPBI Group Team in the past:
- Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD
https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/
- Podcast with Prof. Marcus W. Feldman, PhD, Biology Department, Stanford University, Interview by Gail S. Thornton, PhDc
https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-prof-marcus-w-feldman-phd-biology-department-stanford-university-interview-by-gail-s-thornton-phdc/
- Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc
https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-sudipta-saha-phd-interview-by-gail-s-thornton-phdc-narrators-voice-gail-s-thornton-phdc/ |
| Strategic Focus:
– $500M R&D reinvestment by 2026 targets AI for Productivity
– Part of $7.7B cost savings
– Ethical AI, diverse DBs
– Global biotech advances: China’s AI in CRISPR |
|
Dr. Lev-Ari Prompted @Grok on 11/18/2025:
AI-Driven Cost Savings in Big Pharma
@Grok responded:
AI-Driven Cost Savings in Big PharmaArtificial intelligence (AI) applications across the pharmaceutical value chain—particularly in drug discovery, clinical trials, and operations—have the potential to generate substantial savings for major pharmaceutical companies (often referred to as “Big Pharma”). Based on recent industry reports and analyses from 2024-2025, these savings vary by application but could collectively reach tens of billions annually by the late 2020s. Projections indicate AI could add up to 11% in value relative to revenue for biopharma firms over the next five years through productivity gains and cost reductions. Below, I break down the estimated savings levels by key areas, drawing from credible sources like McKinsey, Deloitte, IQVIA, and others.
-
Clinical Trials
- Annual Industry-Wide Savings: By 2030, AI integration into 60-70% of clinical trials could save the pharmaceutical industry $20-30 billion per year through faster timelines, better patient matching, and reduced administrative costs.
- Per-Trial Cost Reduction: AI can cut trial costs by up to 70% and shorten durations by 80%, enabling quicker regulatory submissions (40% faster) with 50% improved cost efficiency. For example, AstraZeneca reported up to 25% shorter trial durations in cancer drug studies using AI for dose optimization and biomarker identification.
- Specific Efficiency Gains: Feasibility surveys can see 90% time reductions using AI/ML tools.
-
Drug Discovery and Development
- R&D Cost Drop: AI could reduce drug discovery costs by up to 40%, with overall development timelines shrinking from 5 years to 12-18 months (an 80% cut in some cases). From discovery to preclinical candidate stage, timelines can decrease by up to 50%.
- Total Clinical Development Savings: Projected at $25 billion across the sector, driven by AI-accelerated pipelines.
-
Operations and Broader Impacts
- Value Relative to Revenue: Biopharma AI investments may yield up to 11% additional value (e.g., via cost efficiencies and revenue growth) over five years. For related medtech segments, savings could hit 12% of total revenue within 2-3 years.
- Operating Profits Boost: By 2030, AI could add $254 billion in annual operating profits industry-wide through productivity jumps (e.g., 50-100% in quality control) and lead time reductions (60-70%).
- Time-to-Market: Up to 10% faster overall, with production KPIs improving revenue by 25%.
These estimates assume scaled adoption, with global AI spending in pharma rising from ~$3 billion in 2025 to $22-25 billion by 2027-2030. Challenges like high initial costs and data infrastructure may temper short-term gains, but early adopters (e.g., Pfizer, Novartis) are already seeing ROI. For context, the global pharma market is projected at $1.6 trillion by 2025, so even modest percentages translate to billions in savings. If you need details on a specific AI use case or company, let me know!
SOURCE
https://x.com/i/grok?conversation=1990851703051104519
Dr. Lev-Ari Prompted @Grok on 11/17/2025:
Pfizer, its competitors by size, market share, product lines and Investment in AI technologies
Grok responded
https://x.com/i/grok?conversation=1990458795936354506
Overview of Pfizer and Key CompetitorsPfizer is one of the world’s largest pharmaceutical companies, with a strong focus on innovative medicines and vaccines. Its primary competitors include Merck & Co., Johnson & Johnson (J&J), Roche, Novartis, and now AstraZeneca, based on revenue leadership and market overlap in areas like oncology, immunology, and vaccines. These companies dominate the global pharmaceutical industry, which is projected to reach $1.21 trillion in revenue by 2025. Below, I compare them across size (measured by 2024 revenue and employees), market share (approximate global pharma share based on 2024 revenues), product lines (key therapeutic areas and top products), and investments in AI technologies. Data reflects the latest available figures as of late 2025.
Here are the same comparisons with more concise tables (2024 data, latest available as of Nov 2025):
Size (2024 Revenue & Employees)
|
Company
|
Revenue (USD B)
|
Employees
|
|
Merck & Co.
|
64.2
|
70,000
|
|
Pfizer
|
63.6
|
88,000
|
|
Roche
|
~58.3
|
103,000
|
|
J&J (pharma only)
|
57.8
|
138,000
|
|
AstraZeneca
|
54.1
|
94,300
|
|
Novartis
|
~50.0
|
76,000
|
Approx. Global Pharma Market Share
|
Company
|
Share %
|
|
Merck & Co.
|
4.3
|
|
Pfizer
|
4.2
|
|
J&J / Roche
|
3.9
|
|
AstraZeneca
|
3.6
|
|
Novartis
|
3.3
|
Key Product Lines & Top Sellers (2024 revenue, USD B)
|
Company
|
Main Areas
|
Top Products (revenue)
|
|
Pfizer
|
Vaccines, cardiology, oncology
|
Eliquis (7.3), Prevnar (6.4), Vyndaqel (5.4)
|
|
Merck & Co.
|
Oncology, vaccines
|
Keytruda (25.0), Gardasil (8.6)
|
|
J&J
|
Immunology, oncology
|
Stelara (10.9), Darzalex (9.7)
|
|
AstraZeneca
|
Oncology, CVRM, respiratory
|
Farxiga (7.7), Tagrisso (6.6), Enhertu (4.0)
|
|
Roche
|
Oncology, neurology, hemophilia
|
Ocrevus (5.7), Hemlibra (4.0)
|
|
Novartis
|
Cardiology, immunology
|
Entresto (6.6), Cosentyx (5.2)
|
AI Investment Snapshot (2025)
|
Company
|
AI Highlights (2025)
|
Scale/Impact
|
|
Pfizer
|
AI cuts discovery from years → 30 days; heavy partnerships
|
Leader in adoption
|
|
AstraZeneca
|
Evinova AI trials unit; $2.5B AI Beijing hub; 12k+ staff upskilled
|
Very aggressive (>85% productivity gain)
|
|
Merck & Co.
|
Gen-AI for protocols; 20+ AI “blockbusters” in pipeline
|
>$1.2B spend
|
|
J&J
|
900+ AI projects → $500M savings; surgical AI training
|
Broad internal rollout
|
|
Roche
|
AI diagnostics + drug discovery; $55M Manifold Bio deal
|
Strong in diagnostics
|
|
Novartis
|
AI pipeline acceleration; data-science alliances
|
Integrated into $10B R&D
|
Searched for “(“AI” OR “artificial intelligence”) (“biotech” OR “biotechnology”) startup since:2025-01-01″
10 results
AI in Biotech Startups:
2025 LandscapeArtificial Intelligence (AI) is revolutionizing biotech startups by accelerating drug discovery, optimizing clinical trials, and enabling personalized medicine. In 2025, AI applications like generative models for molecule design and predictive analytics for protein structures are slashing R&D timelines from years to months, reducing costs by up to 30%, and boosting success rates. The sector blends biology’s complexity with AI’s data-crunching power, drawing massive VC interest amid ethical debates on gene editing and biosecurity.Key Trends
- Explosive Funding Growth: U.S. healthcare VC hit $23B in 2024, with ~30% ($5.6B) targeting AI-biotech—nearly triple 2023 levels. Biopharma startups raised $24.2B across 568 deals, up from $10.1B in 2023. Q3 2025 saw $97B global VC (up 38% YoY), half to AI firms. Mega-rounds ($100M+) surged, focusing on drug discovery and rare diseases.
- Market Expansion: Global AI-biotech market: $4.6B in 2025, projected to $11.4B by 2030 (20% CAGR). Biotech overall to $5.85T by 2034 (13.6% CAGR), driven by AI in gene editing, microbiome therapeutics, and automation.
- Compute Demands: Biotech AI requires massive GPUs; Nvidia’s AI sales hit $41.1B in one 2025 quarter (56% YoY). Startups lean on cloud partnerships (e.g., AWS-Recursion) or in-house clusters, with hyperscalers eyeing $3-4T infrastructure by 2030.
- Regional Hotspots: North America leads (42% share) via FDA support and hubs like Boston/SF; Europe grows via funding/regulatory advances; Asia (e.g., China) via collaborations.
- Challenges & Ethics: Selective funding favors clinically validated firms; rising M&A (big pharma acquiring AI startups); ethical scrutiny on AI gene editing (e.g., CRISPR enhancements).
Notable Startups & Recent Funding
Here’s a snapshot of standout AI-biotech startups, highlighting innovations and 2024-2025 funding:
|
Startup
|
Focus Area
|
Key Innovation
|
Recent Funding (2025)
|
|
Insilico Medicine
|
Drug Discovery
|
Generative AI for novel molecules
|
$100M+ Series D (ongoing)
|
|
Recursion Pharmaceuticals
|
Phenomics & Drug Repurposing
|
AI mapping diseases via cell images
|
$50M partnership w/ Nvidia
|
|
Absci Corp.
|
Protein Design
|
AI-generated antibodies/proteins
|
$20M from AMD (Jan 2025)
|
|
TandemAI
|
Drug Discovery
|
ML for molecular simulation
|
$22M Series A extension
|
|
Red Queen Bio
|
Biosecurity
|
AI for pathogen detection/design
|
$15M Seed led by OpenAI
|
|
Antiverse
|
Antibody Design
|
AI predicting antibody structures
|
Deal w/ Nxera Pharma (2024)
|
|
Deep Genomics
|
Genomics
|
AI extracting insights from DNA data
|
VC round undisclosed
|
|
Aizen Therapeutics
|
Molecule Generation
|
Proprietary AI engines for trials
|
Early-stage VC
|
These firms exemplify AI’s shift from hype to pipeline impact—e.g., Insilico’s AI-discovered drug entered Phase II trials in record time.Emerging ApplicationsAI’s top uses in biotech startups:
- Drug Discovery: ML predicts drug-target interactions (e.g., AlphaFold-inspired tools cut screening costs 70%).
- Genomics & Diagnostics: AI analyzes vast datasets for rare variants, powering precision oncology.
- Clinical Trials: Predictive models optimize patient matching, reducing failures by 20-30%.
- Synthetic Biology: AI designs custom microbes for therapeutics or biofuels.
- Automation Labs: AI-robotics handle experiments autonomously, boosting throughput 10x.
Future Outlook
2025 signals a “quality over quantity” pivot: Investors prioritize AI startups with real-world data and partnerships (e.g., Y Combinator, Google for Startups). M&A will rise as big pharma (Pfizer, Merck) snaps up talent. Yet, compute shortages and regs (e.g., FDA AI guidelines) pose hurdles. For founders, blending AI with wet-lab validation is key to unlocking the next wave of breakthroughs—potentially curing diseases once deemed untreatable. If you’re building or investing, focus on
- rare diseases or
- oncology
for the hottest bets.
Additional Competitors by Product Line
@Grok Response
https://x.com/i/grok/share/Ple3W4IDlwhyjUwBUU4JAg2OD
Key Products and Focus AreasPfizer’s portfolio spans immunology, oncology, cardiology, endocrinology, neurology, and vaccines. In 2024, its top revenue generators included:
- Eliquis (apixaban, blood thinner): $7.3 billion (11% of total revenue).
- Prevnar family (pneumococcal vaccines): $6.4 billion (10%).
- Paxlovid (COVID-19 antiviral): $5.7 billion (9%).
- Vyndaqel (tafamidis, for rare heart disease): $5.4 billion (8%).
- Comirnaty (COVID-19 vaccine): $5.3 billion (8%).
- Ibrance (palbociclib, breast cancer drug): $4.3 billion (6%).
The company is investing heavily in AI-driven drug discovery (e.g., 2024 partnerships with NVIDIA and Saama) and next-gen therapies like RSV vaccines, gene therapies for muscular dystrophy, and oral GLP-1 drugs for obesity/diabetes. Challenges include patent expirations (e.g., Eliquis in 2026-2028) and biosimilar competition, but Pfizer’s diversified pipeline positions it for mid-single-digit growth in 2025.Pfizer’s Main CompetitorsPfizer operates in a highly competitive $1.5 trillion global pharma market, where rivals vie for dominance in oncology, vaccines, immunology, and emerging areas like obesity and gene therapy. Its primary competitors are fellow “Big Pharma” giants, often overlapping in therapeutic areas. Based on revenue, market share, and direct product rivalries, here are the top ones (ranked roughly by 2024 revenue for context):
|
Competitor
|
Headquarters
|
2024 Revenue (Pharma Segment)
|
Key Strengths & Overlaps with Pfizer
|
Notable Products
|
|
Johnson & Johnson (J&J)
|
New Brunswick, NJ, USA
|
$88.8 billion (total; pharma ~$57.8 billion)
|
Diversified (pharma, devices, consumer); strong in oncology, immunology, vaccines. Competes directly in blood thinners and cancer therapies.
|
Darzalex (multiple myeloma), Stelara (psoriasis), Imbruvica (blood cancer).
|
|
Merck & Co.
|
Rahway, NJ, USA
|
$64.2 billion
|
Oncology leader; vaccines and antivirals. Keytruda outsells Pfizer’s Ibrance; rivals in HPV/pneumococcal vaccines.
|
Keytruda (immunotherapy, $29.5 billion), Gardasil (HPV vaccine).
|
|
Roche Holding AG
|
Basel, Switzerland
|
~$68 billion (group; pharma ~$50 billion)
|
Diagnostics + pharma powerhouse; dominates oncology and neurology. Competes in antibody-drug conjugates post-Pfizer’s Seagen buy.
|
Ocrevus (MS), Hemlibra (hemophilia), Avastin (cancer).
|
|
AbbVie Inc.
|
North Chicago, IL, USA
|
$56.3 billion
|
Immunology and neuroscience focus; biosimilars erode shared markets like Humira vs. Pfizer’s Enbrel alternatives.
|
Humira (rheumatoid arthritis), Skyrizi (psoriasis), Rinvoq (arthritis).
|
|
Novo Nordisk A/S
|
Bagsværd, Denmark
|
~$40 billion (est.)
|
Diabetes/obesity specialist; exploding GLP-1 demand challenges Pfizer’s emerging obesity pipeline.
|
Ozempic/Wegovy (semaglutide for diabetes/weight loss).
|
|
Eli Lilly and Co.
|
Indianapolis, IN, USA
|
~$45 billion (est.; projecting $58-61 billion in 2025)
|
Diabetes/obesity and neurology; Mounjaro rivals Pfizer’s danuglipron in GLP-1 space.
|
Mounjaro/Zepbound (tirzepatide), Verzenio (breast cancer).
|
|
AstraZeneca PLC
|
Cambridge, UK
|
$50.95 billion
|
Oncology, respiratory, and cardiovascular; Tagrisso competes with Pfizer’s Lorbrena in lung cancer.
|
Tagrisso (lung cancer), Farxiga (diabetes/heart), Imfinzi (immunotherapy).
|
|
Novartis AG
|
Basel, Switzerland
|
~$48 billion
|
Gene therapy and immunology; rivals in rare diseases and oncology.
|
Cosentyx (psoriasis), Entresto (heart failure), Kisqali (breast cancer).
|
|
Bristol-Myers Squibb (BMS)
|
New York, NY, USA
|
$47.8 billion
|
Oncology and immunology; Opdivo directly competes with Pfizer’s Bavencio in checkpoint inhibitors.
|
Opdivo (immunotherapy), Eliquis (co-developed with Pfizer, but BMS handles ex-US).
|
|
Sanofi S.A.
|
Paris, France
|
~$46 billion
|
Vaccines and rare diseases; Dupixent challenges in immunology; rivals Prevnar in pneumococcal vaccines.
|
Dupixent (atopic dermatitis), Lantus (diabetes).
|
These competitors collectively hold over 50% of the global pharma market share. Emerging threats include biotech upstarts like Moderna (mRNA vaccines, directly rivaling Comirnaty) and generics firms like Teva (eroding post-patent revenues). In 2025, competition intensifies in obesity (Novo/Lilly lead) and oncology (Merck/Roche dominate), with tariffs and pricing pressures (e.g., US executive orders) affecting all.Pfizer’s edge comes from its scale and partnerships (e.g., BioNTech for mRNA), but it must navigate revenue dips from COVID fade-out and biosimilars. For 2025 projections, analysts expect 6-9% growth across the sector, with Pfizer targeting modest gains through oncology expansions. If you’d like deeper dives on specific rivals, financials, or products, let me know!
AI Acquisitions by Big Pharma
2d • 2 days ago • Visible to anyone on or off LinkedIn
Article was summarized by @Grok on 11/29/2025
Summary of the Article:
“Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma”
This November 15, 2025, article on PharmaceuticalIntelligence.com (curated by LPBI Group) makes a compelling case for leveraging LPBI’s decade-plus of expert-curated digital IP as a high-fidelity, rights-clean training corpus to supercharge AI-driven innovation in Big Pharma. It contrasts the limitations of generic LLMs (like GPT) with the need for domain-specific, ontologized biomedical data, positioning LPBI’s assets as a “defensible moat” for accelerating R&D in drug discovery, precision medicine, and beyond. The piece blends market analysis of pharma giants with a deep dive into LPBI’s portfolio, emphasizing its multimodal, metadata-rich structure for NLP, knowledge graphs, and fine-tuning SLMs/LLMs.IntroductionThe thesis: In an era where AI investments in pharma (e.g., Eli Lilly’s aggressive funding) focus on slashing R&D timelines by 60%+ in target discovery and 25% in drug design, LPBI’s proprietary corpus—built since 2012 via human curation, digitization, and ontology mapping—offers unmatched authenticity over web-scraped data. It addresses GPT’s biomedical shortcomings (e.g., failing to infer fusion proteins or noncanonical pathways without curated inputs) and highlights LPBI’s foresight in text analysis for generative AI augmentation. A key quote from Data2Discovery: “We are able to improve drug discovery now as well as demonstrating new fast-cycle AI-driven processes that will have a revolutionary impact on drug discovery if fully implemented.”Portfolio OverviewLPBI’s ~9 GB, debt-free, multimodal corpus is privately held, expert-curated (e.g., by Prof. Marcus W. Feldman and Dr. Stephen J. Williams), and ingest-ready for AI pre-training/evaluations. It spans five key asset classes, each with metadata exports, timestamps, crosslinks, and centralized rights for model training:
|
Asset Class
|
Description & Size
|
Unique Value Proposition
|
|
I: Scientific Articles
|
6,250+ articles on PharmaceuticalIntelligence.com (~2.5M views); covers genomics, oncology, immunology, etc.
|
Live ontology, author/role labels, view histories; enables temporal NLP for trend analysis.
|
|
II: e-Books
|
48 bilingual (English/Spanish) volumes in 5 BioMed e-Series (e.g., Series A: Cardiovascular, 6 vols., $515 total; Series E: Patient-Centered, 4 vols., $274); 151,000+ page downloads; 2,728 articles.
|
Peer-reviewed, senior-editor TOCs; pay-per-view model proves demand; ideal for entity-relationship extraction.
|
|
III: e-Proceedings
|
100+ from biotech/genomics conferences (2013–2025); +50 tweet collections as speaker quotes with affiliations.
|
Real-time event curation; captures emerging insights for knowledge graph augmentation.
|
|
V: Biological Images
|
7,500+ images in Digital Art Media Gallery; embedded as prior art in texts.
|
Expert-contextualized visuals; supports multimodal AI for image-text pairing in diagnostics.
|
|
X: Audio Podcasts
|
300+ interviews with scientific leaders (e.g., Nobel laureates like Jennifer Doudna); classified by themes like CRISPR, mRNA vaccines.
|
Transcripts + NLP WordClouds; adds auditory/verbal depth for voice-enabled AI copilots.
|
The portfolio’s “living ontology” allows seamless integration into tools like InfraNodus for concept mapping.AI Training RelevanceUnlike PubMed’s unstructured dumps, LPBI’s assets are pre-annotated for concept extraction (e.g., gene-disease-drug dyads), reducing hallucinations and bias in LLMs. A case study integrates curation with ChatGPT-5: Manual ontology + knowledge graphs uncovered novel WNT/Hedgehog interactions in lung cancer, generating research questions like: “How does the interaction between [[EGFR]] mutations and sex-specific gene alterations, including [[RBM10]], influence treatment outcomes in lung adenocarcinoma?” This hybrid approach outperforms solo GPT, proving the corpus’s role in trustworthy biomedical inference.Applications
- Drug Discovery: ML prompts on dyads to mimic Pfizer’s AI (e.g., reducing discovery from years to months); supports biologics/cell therapies.
- Precision Medicine: 547 articles for patient subtyping; 3,615 disease-focused pieces for predictive modeling.
- Diagnostics & Rare Diseases: 560 rare disease articles + 30 on ATTR-CM for early detection (e.g., via Pfizer’s ASPIRE AI).
- Clinical/Regulatory: Streamlines trials, evidence synthesis, and content generation (e.g., via Pfizer’s “Charlie” copilot, saving hours on lit reviews).
- Generative Tools: Fine-tune for compliant, domain-aware outputs in medical affairs/safety.
Challenges & Solutions
- Data Quality/Bias: Unstructured text leads to GPT errors; solved by expert curation + ontology for accurate, diverse inputs.
- Regulatory Compliance: Rights fragmentation; addressed via LPBI’s centralized assignment for NDA-secure licensing.
- Scalability: Generic data overload; LPBI’s focused, high-signal corpus enables fast-cycle AI without noise.
Recommendations
Urge Big Pharma (e.g., Pfizer, Merck—table highlights Merck’s $64.2B revenue, Keytruda focus) to acquire the full portfolio for end-to-end knowledge bases, or license under NDA for SLM/LLM training (English/Spanish).
- Emphasizes “buy the moat” for competitive edge in 2025’s 6–9% sector growth (obesity/oncology hotspots).
Contact: avivalev-ari@alum.berkeley.edu.
Conclusion
LPBI’s corpus isn’t just data—it’s a “scientific revolution enabler,” blending human creativity with AI for transformative pharma impact. Validated on extraction tasks, it’s primed for partnerships, outshining combinatorial predictions with authentic, curated depth. This article builds on prior LPBI mappings (e.g., our podcast TOC summary), reinforcing the portfolio’s strategic fit for AI.
For deeper analysis or related assets, let me know!
Like this:
Like Loading...
Read Full Post »
2012pharmaceutical
sjwilliamspa
AI in Pharma: From Tool to Value Creator 🚀
Over the past 5 years, pharma’s AI footprint has expanded rapidly and the investment trends tell a clear story.
💡 ~60% of collaborations and acquisitions now focus on TargetDiscovery and Validation — pharma’s main frontier to shorten early-stage R&D timelines and boost success rates through PrecisionBiology.
⚗️ The second-largest area (~25%) centers on AI-driven DrugDesign and MoleculeOptimization, where algorithms accelerate CandidateSelection, refine molecular properties, and enable NewModalities such as Biologics and CellAndGeneTherapies.
🏆 Among top players, Eli Lilly and Company stands out as the most active investor — making AI a true StrategicCapability, not just another research tool.
The takeaway?
AI isn’t just supporting pharma anymore, it’s reshaping it.
Source: Bita Sehat, PhD, MBA
hashtag#ai hashtag#lifesciences hashtag#pharmaceuticals hashtag#techbio hashtag#biotech